Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade
Background Despite the survival benefits observed with immune checkpoint blockade (ICB) treatment—programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1), many patients with cancer have not benefited from these agents because of impaired antigen presentation and other resistance mechanis...
| Principais autores: | , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
BMJ Publishing Group
2022-12-01
|
| coleção: | Journal for ImmunoTherapy of Cancer |
| Acesso em linha: | https://jitc.bmj.com/content/10/12/e005447.full |